| |
Newsroom /
Health and Fitness
/
Healthcare
/
Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015
Epilepsy - Drug Pipeline Analysis and Market Forecasts to 2015 
Epilepsy Therapeutics Market holds Significant Low Market Potential
Hyderabad,
AP,
India
(prbd.net)
30/12/2009
"Epilepsy or seizure disorder is a common Central Nervous System (CNS) disorder"
Epilepsy or seizure disorder is a common Central Nervous System (CNS) disorder and is usually diagnosed after a person has had at least two seizures not caused by known conditions. The seizure in epilepsy may be related to a brain injury or a familial history but generally its cause is completely unknown. There are two types of epilepsy: generalized (comprising grand mal and petit mal; approximately 65% of patients) and partial (comprising simple and complex; approximately 35% of patients). In the current market, generalized epilepsy is fairly well controlled, though sometimes at the expense of unpleasant side effects. The same is not true for partial epilepsy. The epilepsy market has relatively medium unmet need. Many new antiepileptic drugs (AEDs) have become available over the past 15 years, and the pipeline for new AEDs continues to be growing at a steady rate.
The antiepileptic drug market is currently under pressure from generic competition, which typically has 40-50% cheaper drugs then the branded products. This can drive down prices and decrease sales of branded drugs. However, currently available medication is not only indended for epilepsy but also for other conditions such as pain and bipolar disorder. The approval of antiepileptic drugs for new indications, for use as monotherapy, refractory epilepsy, and in children (LGS), will potentially provide growth for the epilepsy market. Currently available marketed AEDs result in seizure-free status in no more than 15 to 20% of patients with partial complex seizures. Overall, across all types of epilepsy, approximately 30% of epileptic patients are still not seizure free, despite a large range of old and new drugs.
GlobalData’s analysis estimated the global epilepsy market to be at $10.9 billion in 2008 and is forecast to grow by 1.7% annually for the next seven years to reach $12.3 billion by 2015. This low growth is primarily attributed to successive patent expiries beginning in 2013 with Lyrica, Pfizer’s primary product. This drug generated approximate revenues of about $2.5 billion in 2008 accounting for 25% of the market share. Following this there is forecast to be a very slow increase in growth owing to competition from generics which is predicted to increase over the next two years. Primary reasons for the market not to show remarkable reduction in growth is attributed to the equal distribution of market share among the top drug contenders, most of whom have generic substitutes.
GlobalData, the industry analysis specialist’s new report, “Epilepsy – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global epilepsy market. The report identifies the key trends shaping and driving the global epilepsy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global epilepsy sector.
Or
Visit our Report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|